Inventor

Donald Payan

Inventor

Hillsborough, CA, US

Overview

2000–2021

Patent span

Chemistry

Primary field (CPC C)

Patents· 87 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%

C07DHeterocyclic compounds23%

A61KPreparations for medical, dental or toiletry purposes20%

C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium14%

C12NMicroorganisms or enzymes4%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms3%

G01NInvestigating or analysing materials by determining their chemical or physical properties3%

C07BGeneral methods of organic chemistry2%

C07KPeptides2%

C12YEnzymes1%

PatentTitleYear

11,111,305Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex2021 11,007,1932,4-pyrimidinediamine compounds and their uses2021 10,941,134AMPK-activating heterocyclic compounds and methods for using the same2021 10,858,3352,3-Disubstituted pyridine compounds as TGF-b inhibitors and methods of use2020 10,828,3012,4-pyrimidinediamine compounds and their uses2020 10,792,282Protein kinase C inhibitors and uses thereof2020 10,709,7032,4-pyrimidinediamine compounds and their uses2020 10,682,3502,4-pyrimidinediamine compounds and their uses2020 10,414,758Compounds and method for treating autoimmune diseases2019 10,377,742AMPK-activating heterocyclic compounds and methods for using the same2019 10,369,1482,4-pyrimidinediamine compounds and their uses2019 10,314,8402,4-pyrimidinediamine compounds and their uses2019 10,233,1702,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use2019 10,040,766Ubiquitination inhibitors2018 10,005,777Protein kinase C inhibitors and uses thereof2018 9,913,842'2,4-pyrimidinediamine compounds and their uses'2018 9,890,144'Compounds and method for treating autoimmune diseases'2018 9,878,992'GDF-8 inhibitors'2018 9,682,976'Protein kinase C inhibitors and uses thereof'2017 9,586,908'2,4-pyrimidinediamine compounds and their uses'2017 9,566,278'Protein kinase C inhibitors and uses thereof'2017 9,540,334'2,4-pyrimidinediamine compounds and their uses'2017 9,518,040'GDF-8 inhibitors'2016 9,511,058'Methods for using carboxamide, sulfonamide and amine compounds'2016 9,499,493'2,4-pyrimidinediamine compounds and their uses'2016 9,416,112'2,4-pyrimidinediamine compounds and their uses'2016 9,409,884'5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them'2016 9,353,112'Synthesis of polycyclic alkaloids'2016 9,346,765'2,4-pyrimidinediamine compounds and their uses'2016 9,321,763'Protein kinase C inhibitors and uses thereof'2016 9,266,856'AMPKâ€”activating heterocyclic compounds and methods for using the same'2016 9,169,249'Protein kinase C inhibitors and uses thereof'2015 9,162,989'2,4-Pyrimidinediamine compounds and their uses'2015 9,145,433'GDF-8 inhibitors'2015 9,133,133'2,4-pyridinediamine compounds and their uses'2015 9,040,550'2,4-pyrimidinediamine compounds and their uses'2015 9,018,204'2,4-pyrimidinediamine compounds and their uses'2015 8,993,585'Cyclic amine substituted pyrimidinediamines as PKC inhibitors'2015 8,987,303'AMPK-activating heterocyclic compounds and methods for using the same'2015 8,980,921'AMPK-activating heterocyclic compounds and methods for using the same'2015 8,927,564'Synthesis of polycyclic alkaloids'2015 8,853,397'2,4-pyrimidinediamine compounds and their uses'2014 8,835,430'2,4-pyrimidinediamine compounds and their uses'2014 8,822,685'2,4-pyrimidinediamine compounds and their uses'2014 8,809,370'AMPK-activating heterocyclic compounds and methods for using the same'2014 8,796,254'Methods for using carboxamide, sulfonamide and amine compounds'2014 8,791,136'Substituted pyridine, pyridazine, pyrazine and pyrimidine compounds and methods for using the same'2014 8,575,165'Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds'2013 8,557,806'Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds'2013 8,546,433'Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer'2013 8,481,521'Methods of treating cell proliferative disorders'2013 8,334,238'Multiparameter FACS assays to detect alterations in cellular parameters and to screen small molecule libraries'2012 8,334,296'2,4-pyrimidinediamine compounds and their uses'2012 8,334,297'2,4-pyrimidinediamine compounds for treatment of inflammatory disorders'2012 8,227,455'Methods of treating cell proliferative disorders'2012 8,188,276'2,4-pyrimidinediamine compounds and their uses'2012 8,148,525'2,4-pyrimidinediamine compounds and their uses'2012 7,863,222'shRNA library'2011 7,825,116'N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines'2010 7,820,819'2,4-pyrimidinediamine compounds and their uses'2010 7,812,029'Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds'2010 7,745,196'Methods and compositions for identifying peptide modulators of cell surface receptors'2010 7,655,797'Intermediates for making 2,4-pyrimidinediamine compounds'2010 7,642,351'2,4-Pyrimidinediamine compounds and their uses'2010 7,589,200'5-Fluoro-4N-phenyl-4-pyrimidineamine compounds'2009 7,557,210'2,4-pyrimidinediamine compounds and their uses'2009 7,550,460'2,4-pyrimidinediamine compounds and their uses'2009 7,517,886'Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds'2009 7,498,435'2,4-pyrimidinediamine compounds and their uses'2009 7,485,724'2,4-pyrimidinediamine compounds and their uses'2009 7,435,814'2,4-Pyrimidinediamine compounds and their uses'2008 7,332,484'2,4-pyrimidinediamine compounds and their uses'2008 7,329,671'2,4-pyrimidinediamine compounds and their uses'2008 7,329,672'2,4-pyrimidinediamine compounds and their uses'2008 7,243,112'Multidimensional biodata integration and relationship inference'2007 7,132,234'Methods and compositions for the identification of anti-poxvirus agents'2006 7,060,827'Intermediates useful for making 2,4-pyrimidinediamine compounds'2006 7,034,145'Directionally cloned random cDNA expression vector libraries, compositions and methods of use'2006 6,969,584'Combinatorial enzymatic complexes'2005 6,897,031'Multiparameter FACS assays to detect alterations in exocytosis'2005 6,855,495'Toso as a target for drug screening'2005 6,808,906'Directionally cloned random cDNA expression vector libraries, compositions and methods of use'2004 6,737,240'Methods of screening for a multi-drug resistance conferring peptide'2004 6,555,314'Toso as a target for drug screening'2003 6,455,263'Small molecule library screening using FACS'2002 6,316,223'Mammalian protein interaction cloning system'2001 6,114,111'Mammalian protein interaction cloning system'2000

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2000–2021Patents assigned to RIGEL PHARMACEUTICALS INC (85)· patent assignee history

2000–2021Based in Hillsborough, CA, US· patent location history

2012–2020Patents assigned to SINGH RAJINDER (16)· patent assignee history

2012–2020Patents assigned to BHAMIDIPATI SOMASEKHAR (12)· patent assignee history

2012–2020Patents assigned to LI HUI (12)· patent assignee history

2012–2020Patents assigned to PAYAN DONALD (10)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
RIGEL PHARMACEUTICALS INC	85	2000–2021
SINGH RAJINDER	16	2012–2020
BHAMIDIPATI SOMASEKHAR	12	2012–2020
LI HUI	12	2012–2020
PAYAN DONALDself	10	2012–2020

Locations

Location	Patents	Span
Hillsborough, California, US	87	2000–2021